I am a
Home I AM A Search Login

Papers of the Week


2022 Nov 30


BMC Med


20


1

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

Authors

Lovell JF, Baik Y O, Choi S K, Lee C K, Lee J-Y, Miura K, Huang W-C, Park Y-S, Woo S-J, Seo S H, Kim J-O, Song M, Kim C-J, Choi J-K, Kim J, Choo E J, Choi J-H
BMC Med. 2022 Nov 30; 20(1):462.
PMID: 36447243.

Abstract

Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes.